COMMUNIQUÉS West-GlobeNewswire

ICPO Foundation partners with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center
04/07/2024
This collaboration enhances global educational benchmarks in radiotheranostics and aims to expand patient access to a new era of effective cancer therapeutics in South Africa. July 4, 2024 – Wiesbaden, Germany, and [...]
Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
04/07/2024
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that it received a notification letter dated June 27, 2024, from the Listings Qualifications Department (the “ [...]
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
04/07/2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat [...]
Assure Announces Reverse Stock Split to support Continued Listing on NASDAQ
04/07/2024
DENVER, July 03, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring ( “IONM ”) and remote neurology services, today announced that [...]
VitalHub Corp. Announces Results of Annual General and Special Meeting of Shareholders
03/07/2024
TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) today reported a summary of the voting results of its Annual General and Special Meeting of Shareholders [...]
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
03/07/2024
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2024
NAARDEN, The Netherlands and MIAMI, July 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
03/07/2024
SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of 48,453 shares of common [...]
DiagnaMed Cancels Previously Announced Private Placement
03/07/2024
TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announces it has cancelled [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/07/2024
WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
CloudMD Receives Court Approval of Proposed Transaction with CPS Capital
03/07/2024
TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, Frankfurt: 6PH) (the “ Company ” or “ CloudMD ”), an innovative health services company transforming the delivery of care, is [...]
OPTIMAS Now Available from The Peer Group
03/07/2024
Give Your Skin a More Youthful, Revitalized Appearance with Breakthrough Radiofrequency Microneedling Skin Treatments from The Northern New Jersey Team FLORHAM PARK, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- The Peer [...]
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/07/2024
CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare [...]
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/07/2024
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to [...]
Sharps Technology Receives Purchase Orders for 1 Million SecureGard Syringes for 2024 Delivery
03/07/2024
Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies issues purchase orders for 1mL SecureGard ultra-low waste, smart safety syringes First 100k unit shipment is scheduled for late July, with [...]
Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024
03/07/2024
Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com Date Total of shares [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 1er juillet 2024
03/07/2024
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext Paris (Compartiment C - Code ISIN : FR001400K4B1 – Symbole : PHXM) Site web : www.phaxiam.com Date Nombre total d’ [...]
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
03/07/2024
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and Nantes, France, 3 July 2024 – Today Boehringer Ingelheim [...]
OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer
03/07/2024
OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer Nantes, France et Ingelheim, Allemagne – le 3 juillet [...]

Pages